LEADER 04315nam 22004695 450 001 9910350239403321 005 20200706142901.0 010 $a981-13-1489-6 024 7 $a10.1007/978-981-13-1489-6 035 $a(CKB)4100000007104049 035 $a(DE-He213)978-981-13-1489-6 035 $a(MiAaPQ)EBC5560083 035 $a(PPN)231458924 035 $a(EXLCZ)994100000007104049 100 $a20181019d2019 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAdvances in Diagnosis and Management of Cutaneous Adverse Drug Reactions$b[electronic resource] $eCurrent and Future Trends /$fedited by Neil H. Shear, Roni P. Dodiuk-Gad 205 $a1st ed. 2019. 210 1$aSingapore :$cSpringer Singapore :$cImprint: Adis,$d2019. 215 $a1 online resource (XII, 314 p. 95 illus., 91 illus. in color.) 311 $a981-13-1488-8 327 $aSection I. Introduction -- 1. Introduction: Classification, Terminology, Epidemiology and Etiology of Cutaneous Adverse Drug Reactions -- Section II. Pathomechanisms of Cutaneous Adverse Drug Reactions -- 2. Immunology of Cutaneous Adverse Drug Reactions -- 3. Pharmacogenomics and Cutaneous Adverse Drug Reactions -- 4 Viral Reactivation in Cutaneous Adverse Drug Reactions -- 5. Using Technology to Learn About Immunology of Cutaneous Adverse Drug Reactions -- Section III. Clinical Perspectives of Cutaneous Adverse Drug Reactions -- 6. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (Epithelial Necrolysis) -- 7. Drug Reaction with Eosinophilia and Systemic Symptoms -- 8. Acute Generalized Exanthematous Pustulosis -- 9. Urticarial Reactions to Drugs -- 10. Dermatological Adverse Events from Cancer Treatments -- 11. Cutaneous Adverse Drug Reactions in Pediatric Population -- 12. Cutaneous Drug Reactions in the Elderly -- 13. Cutaneous Adverse Drug Reactions in Human Immunodeficiency Virus Patients -- 14. Cutaneous Adverse Drug Reactions from Anti-Tuberculosis Treatment -- Section IV. Approach to the Patient with a Cutaneous Adverse Drug Reaction -- 15. Practical Approach to Diagnosis and Management of Cutaneous Adverse Drug Reactions -- 16. Histopathology of Severe Drug Eruptions -- 17. Evaluation of Drug Safety Literature: A Guide for the Practicing Dermatologist -- 18. In vitro and in vivo tests in Cutaneous Adverse Drug Reactions -- 19. Pharmacovigilance of Cutaneous Adverse Drug Reactions -- Section V. Epilogue -- 20. Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions -- 21. Atlas of Cutaneous Adverse Drug Reactions. 330 $aThis resource guides prescribers, pharmacists, and regulators with an update on the recent expansion of basic and clinical knowledge that forms a framework for understanding cutaneous reactions. This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development. The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes. Patients and practitioners often face important decisions about therapy after a drug eruption, including treatment, cross-reactivity with future pharmaceuticals, genetic considerations and dealing with long-term sequelae after a reaction. An international team of experts and leaders in the field share their story and insights into the scientific details and relevant clinical context. 606 $aPharmacy 606 $aPharmacology 606 $aDrug Safety and Pharmacovigilance$3https://scigraph.springernature.com/ontologies/product-market-codes/H69010 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 615 0$aPharmacy. 615 0$aPharmacology. 615 14$aDrug Safety and Pharmacovigilance. 615 24$aPharmacology/Toxicology. 676 $a353.998 702 $aShear$b Neil H$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aDodiuk-Gad$b Roni P$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910350239403321 996 $aAdvances in Diagnosis and Management of Cutaneous Adverse Drug Reactions$91734890 997 $aUNINA